title: Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity.
authors.affiliation: Department of Ophthalmology, Children's University Hospital, Dublin 1, Ireland.
authors.forename: Sarah
authors.initials: S
authors.lastname: Moran
authors.forename: Michael
authors.initials: M
authors.lastname: O'Keefe
authors.forename: Claire
authors.initials: C
authors.lastname: Hartnett
authors.forename: Bernadette
authors.initials: B
authors.lastname: Lanigan
authors.forename: John
authors.initials: J
authors.lastname: Murphy
authors.forename: Veronica
authors.initials: V
authors.lastname: Donoghue
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D016022:Case-Control Studies; D004596:Electroretinography; D005074:Evoked Potentials, Visual; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D058449:Intravitreal Injections; D017075:Laser Coagulation / Q000379:methods*; D054023:Lasers, Semiconductor; D008279:Magnetic Resonance Imaging; D011446:Prospective Studies; D012008:Recurrence; D012178:Retinopathy of Prematurity / Q000145:classification / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab